See the DrugPatentWatch profile for lurbinectedin

According to the prescribing information for lurbinectedin, there are no specific restrictions for administering the drug in outpatient settings [1]. However, it is essential to consider the patient's condition, medical history, and the complexity of the treatment regimen when deciding where to administer the medication.

Lurbinectedin is a chemotherapy agent that is typically administered intravenously every 21 days. The medication requires careful handling and preparation, and patients may need to be monitored for potential side effects during and after treatment [2].

While there are no specific restrictions for administering lurbinectedin in outpatient settings, it is crucial to ensure that the patient receives proper medical care and monitoring during treatment. This may involve working with a healthcare team that has experience in administering chemotherapy and managing potential side effects.

It is also important to note that lurbinectedin is a prescription-only medication, and patients must receive it from a licensed healthcare provider. Additionally, the medication is only available through specialty pharmacies that have the necessary expertise and equipment to handle and prepare the medication [3].

In summary, while there are no specific restrictions for administering lurbinectedin in outpatient settings, it is essential to ensure that patients receive proper medical care and monitoring during treatment. Patients should work with a healthcare team that has experience in administering chemotherapy and managing potential side effects.

Sources:

1. [DrugPatentWatch.com](https://www.drugpatentwatch.com/patent/US-10,544,144-B2/lurbinectedin)
2. [Prescribing Information for Zepzelca (lurbinectedin)](https://www.zepzelca.com/content/dam/zepzelca/us/en/prescribing-information.pdf)
3. [Lurbinectedin: Medication Information](https://www.medicinenet.com/lurbinectedin/article.htm)